AIM: To determine the absolute oral bioavailability (F(p.o.) ) of saxagliptin and dapagliflozin using simultaneous intravenous ¹⁴C-microdose/therapeutic oral dosing (i.v.micro + oraltherap). METHODS: The F(p.o.) values of saxagliptin and dapagliflozin were determined in healthy subjects (n = 7 and 8, respectively) following the concomitant administration of single i.v. micro doses with unlabelled oraltherap doses. Accelerator mass spectrometry and liquid chromatography-tandem mass spectrometry were used to quantify the labelled and unlabelled drug, respectively. RESULTS: The geometric mean point estimates (90% confidence interval) F(p.o) . values for saxagliptin and dapagliflozin were 50% (48, 53%) and 78% (73, 83%), respectively. The i.v.micro had similar pharmacokinetics to oraltherap. CONCLUSIONS: Simultaneous i.v.micro + oraltherap dosing is a valuable tool to assess human absolute bioavailability.
AIM: To determine the absolute oral bioavailability (F(p.o.) ) of saxagliptin and dapagliflozin using simultaneous intravenous ¹⁴C-microdose/therapeutic oral dosing (i.v.micro + oraltherap). METHODS: The F(p.o.) values of saxagliptin and dapagliflozin were determined in healthy subjects (n = 7 and 8, respectively) following the concomitant administration of single i.v. micro doses with unlabelled oraltherap doses. Accelerator mass spectrometry and liquid chromatography-tandem mass spectrometry were used to quantify the labelled and unlabelled drug, respectively. RESULTS: The geometric mean point estimates (90% confidence interval) F(p.o) . values for saxagliptin and dapagliflozin were 50% (48, 53%) and 78% (73, 83%), respectively. The i.v.micro had similar pharmacokinetics to oraltherap. CONCLUSIONS: Simultaneous i.v.micro + oraltherap dosing is a valuable tool to assess human absolute bioavailability.
Authors: Graham Lappin; Wilhelm Kuhnz; Roeline Jochemsen; Johannes Kneer; Ajai Chaudhary; Berend Oosterhuis; Willem Jan Drijfhout; Malcolm Rowland; R Colin Garner Journal: Clin Pharmacol Ther Date: 2006-09 Impact factor: 6.875
Authors: Stephen R Dueker; Le T Vuong; Peter N Lohstroh; Jason A Giacomo; John S Vogel Journal: Adv Drug Deliv Rev Date: 2010-10-31 Impact factor: 15.470
Authors: Sreeneeranj Kasichayanula; Xiaoni Liu; Weijiang Zhang; Marc Pfister; Frank P LaCreta; David W Boulton Journal: Clin Ther Date: 2011-10-26 Impact factor: 3.393
Authors: M Obermeier; M Yao; A Khanna; B Koplowitz; M Zhu; W Li; B Komoroski; S Kasichayanula; L Discenza; W Washburn; W Meng; B A Ellsworth; J M Whaley; W G Humphreys Journal: Drug Metab Dispos Date: 2009-12-08 Impact factor: 3.922
Authors: Graham Lappin; Yoko Shishikura; Roeline Jochemsen; Richard John Weaver; Charlotte Gesson; Brian Houston; Berend Oosterhuis; Ole J Bjerrum; Malcolm Rowland; Colin Garner Journal: Eur J Pharm Sci Date: 2010-03-20 Impact factor: 4.384
Authors: Julie Autmizguine; Daniel K Benjamin; P Brian Smith; Mario Sampson; Philippe Ovetchkine; Michael Cohen-Wolkowiez; Kevin M Watt Journal: Curr Clin Pharmacol Date: 2014
Authors: Cathrine Leonowens; Carolyn Pendry; John Bauman; Graeme C Young; May Ho; Frank Henriquez; Lei Fang; Royce A Morrison; Keith Orford; Daniele Ouellet Journal: Br J Clin Pharmacol Date: 2014-09 Impact factor: 4.335
Authors: L van Andel; H Rosing; Z Zhang; L Hughes; V Kansra; M Sanghvi; M M Tibben; A Gebretensae; J H M Schellens; J H Beijnen Journal: Cancer Chemother Pharmacol Date: 2017-10-17 Impact factor: 3.333
Authors: Ronald de Vries; Johan W Smit; Peter Hellemans; James Jiao; Joseph Murphy; Donna Skee; Jan Snoeys; Juthamas Sukbuntherng; Maarten Vliegen; Loeckie de Zwart; Erik Mannaert; Jan de Jong Journal: Br J Clin Pharmacol Date: 2016-01-15 Impact factor: 4.335
Authors: Tamara Y Milder; Sophie L Stocker; Dorit Samocha-Bonet; Richard O Day; Jerry R Greenfield Journal: Eur J Clin Pharmacol Date: 2019-08-03 Impact factor: 2.953
Authors: Sreeneeranj Kasichayanula; Xiaoni Liu; Frank Lacreta; Steven C Griffen; David W Boulton Journal: Clin Pharmacokinet Date: 2014-01 Impact factor: 6.447